home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.54 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

31 32 Next >

Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm ↗

June 08, 2024

You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 07, 2024

Via Benzinga

Stock Market Revs To Highs On Nvidia, CrowdStrike, Yields: Weekly Review ↗

June 07, 2024

The Nasdaq and S&P 500 hit record highs, but small caps retreated.

Via Investor's Business Daily

Topics Stocks

The 3 Most Undervalued Pharma Stocks to Buy in June 2024 ↗

June 06, 2024

These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.

Via InvestorPlace

Topics Economy

Looking At Viking Therapeutics's Recent Unusual Options Activity ↗

June 06, 2024

Via Benzinga

What's Going On With Viking Therapeutics Stock On Tuesday? ↗

June 04, 2024

Viking Therapeutics reports promising 52-week data from its Phase 2b VOYAGE study on VK2809 for NASH.

Via Benzinga

Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years ↗

May 31, 2024

Via Benzinga

Is Viking Therapeutics Stock a Buy on the Dip? ↗

June 06, 2024

Short-term thinking is creating an intriguing opportunity for investors.

Via The Motley Fool

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? ↗

June 05, 2024

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2024

Via Benzinga

Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug ↗

June 04, 2024

Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease.

Via Investor's Business Daily

The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗

June 04, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

Via InvestorPlace

Market Whales and Their Recent Bets on VKTX Options ↗

May 28, 2024

Via Benzinga

Where Will Viking Therapeutics Be in 5 Years? ↗

May 25, 2024

Could Viking Therapeutics become a big player in the GLP-1 drug market?

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 03, 2024

Via Benzinga

1 Disruptive Biotech Stock to Buy Now, and 1 to Consider ↗

June 03, 2024

Both of these companies could soon set the standard in their fields.

Via The Motley Fool

The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy. ↗

June 03, 2024

There's probably a big enough pie here for everyone to get a slice.

Via The Motley Fool

Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing ↗

May 31, 2024

Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider.

Via InvestorPlace

3 Underappreciated Stocks with Triple-Digit Upside: May 2024 ↗

May 31, 2024

There are plenty of underappreciated stocks on the market. In fact, here are three you may want to consider buying and holding today.

Via InvestorPlace

If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names ↗

May 29, 2024

Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy.

Via InvestorPlace

If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today ↗

May 26, 2024

What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised.

Via The Motley Fool

3 Biotech Stocks That Could Be Millionaire-Makers: May Edition ↗

May 25, 2024

Investors should take a close look at these biotech stocks as they position themselves to provide high returns.

Via InvestorPlace

2 Stocks That Could 10x by 2035 ↗

May 24, 2024

These stocks are very promising, but it's important to consider the downside, too.

Via The Motley Fool

Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound ↗

May 23, 2024

Discover three top Nasdaq stocks to buy. Learn about these investment opportunities and why they’re worth your attention.

Via InvestorPlace

Is It Too Late to Buy Viking Therapeutics Stock? ↗

May 22, 2024

This rising star probably won't burn out soon.

Via The Motley Fool

EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic ↗

May 21, 2024

Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."

Via Benzinga

Topics ETFs

3 Growth Stocks That Could Be Millionaire-Makers: May Edition ↗

May 21, 2024

Investors wanting to get rich should consider a long-term holding in these stocks, each of which has risen exponentially in the last year.

Via InvestorPlace

Wall Street Favorites: 3 Russell 2000 Stocks With Strong Buy Ratings for May 2024 ↗

May 20, 2024

Consider following the recommendations of analysts and buy these small but mighty companies whose stocks are rising.

Via InvestorPlace

3 Monster Stocks in the Making You Can Buy Right Now ↗

May 18, 2024

These stocks might not be small for too much longer.

Via The Motley Fool

Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next? ↗

May 17, 2024

Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason.

Via InvestorPlace

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com